MARKET

ATRA

ATRA

Atara Biotherape
NASDAQ
9.27
-0.03
-0.32%
After Hours: 9.50 +0.23 +2.48% 16:09 07/15 EDT
OPEN
9.29
PREV CLOSE
9.30
HIGH
9.62
LOW
8.77
VOLUME
82.91K
TURNOVER
--
52 WEEK HIGH
18.71
52 WEEK LOW
5.01
MARKET CAP
63.00M
P/E (TTM)
-2.0595
1D
5D
1M
3M
1Y
5Y
1D
Pierre Fabre Pharma Announces Transfer Of IND Application For Tabelecleucel From Its Partner, Atara Biotherapeutics
Benzinga · 19h ago
Atara Biotherapeutics Resubmits Tabelecleucel BLA to FDA, Awaits Regulatory Review Following Manufacturing Collaboration with Pierre Fabre Pharmaceuticals
Reuters · 19h ago
PERRE FABRE PHARMACEUTICALS, INC. ANNOUNCES TRANSFER OF INVESTIGATIONAL NEW DRUG APPLICATION FOR TABELECLEUCEL FROM ATARA BIOTHERAPEUTICS, INC.
Reuters · 19h ago
Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.
PR Newswire · 19h ago
Atara Biotherapeutics: Strategic Advancements and Financial Stability Support Buy Rating
TipRanks · 21h ago
Atara Biotherapeutics Resubmits BLA for Tab-cel to FDA
TipRanks · 1d ago
Atara Biotherapeutics Resubmits BLA For Tabelecleucel
NASDAQ · 1d ago
ATARA BIOTHERAPEUTICS INC - PROJECTS $22M CASH AND INVESTMENTS AS OF JUNE 2025
Reuters · 1d ago
More
About ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company. The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases. Its pipeline products include Ebvallo (Tab-cel), ATA3219, and ATA3431. The Company’s T-cell immunotherapy, tab-cel (tabelecleucel), is in Phase III development for patients with EBV-driven post-transplant lymphoproliferative disease (EBV+ PTLD) who have failed rituximab or rituximab plus chemotherapy, as well as other EBV-driven diseases. Its ATA3219 allogeneic CD19 CAR T immunotherapy, targeting B-cell malignancies and autoimmune diseases, is based on a next-generation 1XX CAR co-stimulatory domain and EBV T-cell platform and does not require TCR or HLA gene editing. ATA3431 is an allogeneic, bispecific CAR directed against CD19 and CD20 for B-cell malignancies and autoimmune disease.

Webull offers Atara Biotherapeutics Inc stock information, including NASDAQ: ATRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATRA stock methods without spending real money on the virtual paper trading platform.